Skip to main content
. 2012 Jul 10;2012:897412. doi: 10.1155/2012/897412

Figure 3.

Figure 3

Discovery and validation of Complement Component 9 as a colorectal cancer biomarker (partially changed from [12]). (a) 2DICAL images with coordinates m/z versus RT. The intensity of the peak of 622 m/z and RT of 56.8 min (indicated by arrows) are clearly different in the plasma samples from healthy controls (left) and colorectal cancer patients (right). (b) Western blot of Complement Component 9 and the loading control α2-macroglobulin. (c) Large-scale RPPA validation of the plasma level of Complement Component 9 using hundreds of clinical samples.